Elucidating the Role of CNOT2 in Regulating Cancer Cell Growth via the Modulation of p53 and c-Myc Expression
Open Access
- 4 August 2025
- journal article
- review article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (8) , 615
Abstract
CNOT2, a central component of the CCR4-NOT transcription complex subunit 2, plays a pivotal role in the regulation of gene expression and metabolism. CNOT2 is involved in various cellular processes, including transcriptional regulation, mRNA deadenylation, and the modulation of mRNA stability. CNOT2 specifically contributes to the structural integrity and enzymatic activity of the CCR4-NOT complex with transcription factors and RNA-binding proteins. Recent studies have elucidated its involvement in cellular differentiation, immune response modulation, and the maintenance of genomic stability. Abnormal regulation of CNOT2 has been implicated in a spectrum of pathological conditions, including oncogenesis, neurodegenerative disorders, and metabolic dysfunctions. This review comprehensively examines the interplay between CNOT2 and p53, elucidating their collaborative and antagonistic interactions in various cellular contexts. CNOT2 is primarily involved in transcriptional regulation, mRNA deadenylation, and the modulation of mRNA stability, thereby influencing diverse biological processes such as cell proliferation, apoptosis, and differentiation. Conversely, p53 is renowned for its role in maintaining genomic integrity, inducing cell cycle arrest, apoptosis, and senescence in response to cellular stress and DNA damage. Emerging evidence suggests that CNOT2 can modulate p53 activity through multiple mechanisms, including the regulation of p53 mRNA stability and the modulation of p53 target gene expression. The dysregulation of CNOT2 and p53 interactions has been implicated in the pathogenesis and progression of various cancers, highlighting their potential as therapeutic targets. Additionally, CNOT2 regulates c-Myc, a well-known oncogene, in cancer cells. This review shows the essential roles of CNOT2 in maintaining cancer cellular homeostasis and explores its interactions within the CCR4-NOT complex that influence transcriptional and post-transcriptional regulation. Furthermore, we investigate the potential of CNOT2 as a biomarker and therapeutic target across various disease states, highlighting its significance in disease progression and treatment responsiveness.Keywords
Funding Information
- National Research Foundation of Korea (RS-2023-00209169)
This publication has 72 references indexed in Scilit:
- Ribosomal protein L5 mediated inhibition of c‐Myc is critically involved in sanggenon G induced apoptosis in non‐small lung cancer cellsPhytotherapy Research, 2020
- Ribosomal protein S2 interplays with MDM2 to induce p53Biochemical and Biophysical Research Communications, 2020
- CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cellsCancer Letters, 2018
- Reviving the guardian of the genome: Small molecule activators of p53Pharmacology & Therapeutics, 2017
- p53 Pulses Diversify Target Gene Expression Dynamics in an mRNA Half-Life-Dependent Manner and Delineate Co-regulated Target Gene SubnetworksCell Systems, 2016
- The Ccr4‐Not complex is a key regulator of eukaryotic gene expressionWIREs RNA, 2016
- The Ccr4–Not complexGene, 2012
- Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 statusArchives of Pharmacal Research, 2011
- Crosstalk between c‐Myc and ribosome in ribosomal biogenesis and cancerJournal of Cellular Biochemistry, 2008
- P53, cell cycle control and apoptosis: Implications for cancerCancer and Metastasis Reviews, 1995